Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.55 |
| ▸ | XDH | P47989 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Catalpol SCHEMBL420515 | 0.91 | HSP90AA1 (0.65) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| Catalpol SCHEMBL29374095 | 0.91 | HSP90AA1 (0.65) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| Catalpol SCHEMBL17231369 | 0.91 | HSP90AA1 (0.65) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| SCHEMBL29478493 | 0.85 | HSP90AA1 (0.59) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| SCHEMBL10307818 | 0.83 | L3MBTL1 (0.53) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| SCHEMBL31345813 | 0.82 | HSP90AA1 (0.70) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| SCHEMBL20382966 | 0.82 | HSP90AA1 (0.55) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| Methylcatalpol SCHEMBL29425882 | 0.80 | HSP90AA1 (0.67) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| SCHEMBL30854808 | 0.76 | L3MBTL1 (0.56) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| SCHEMBL422473 | 0.76 | L3MBTL1 (0.56) | HSP90AA1XDHL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | HSP90AA1 2904/4885XDH 2921/4885L3MBTL1 2860/4885 |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | HSP90AA1 2904/4885XDH 2921/4885L3MBTL1 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.